Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome

Table 1

Baseline characteristics of patients in the study groups.

Variable	Pitavastatin + ezetimibe	Pitavastatin	value
	()	()
Age (y)	65.2 ± 11.3	66.6 ± 12.0	0.4
Men	70 (70.0%)	75 (77.3%)	0.24
BMI (kg/m^2)	23.8 ± 3.3	23.7 ± 4.8	0.86
Hypertension	74 (74.0%)	67 (69.1%)	0.44
Diabetes mellitus	33 (33.0%)	31 (32.0%)	0.88
Smoker	55 (55.0%)	57 (58.8%)	0.59
Family history of CAD	26 (26.0%)	24 (24.7%)	0.84
Prior angina or myocardial infarction	26 (26.0%)	25 (25.8%)	0.97
Prior PCI	22 (22.0%)	24 (24.7%)	0.65
Prior CABG	5 (5.0%)	9 (9.3%)	0.24
Diagnosis on admission
STEMI	48 (48.0%)	32 (33.0%)	0.03
NSTEMI	5 (5.0%)	11 (11.3%)	0.1
UAP	47 (47.0%)	54 (55.7%)	0.22
TIMI risk score	3.6 ± 1.5	3.9 ± 1.7	0.19
Medication
Statin	23 (23.0%)	26 (26.8%)	0.54
Antiplatelet agent	38 (38.0%)	49 (50.5%)	0.08
ACEI/ARB	48 (48.0%)	38 (39.2%)	0.21
CCB	36 (36.0%)	35 (36.1%)	0.99
β-blocker	15 (15.0%)	27 (27.8%)	0.03
Baseline laboratory data
LDL-C (mg/dL)	130.1 ± 31.3	131.9 ± 27.7	0.67
HDL-C (mg/dL)	45.6 ± 12.0	46.2 ± 11.0	0.72
Triglycerides (mg/dL)	122.9 ± 71.3	124.4 ± 71.7	0.88
eGFR (mL/min/1.73 m^2)	57.2 ± 16.0	58.9 ± 18.3	0.49
UA (mg/dL)	5.8 ± 1.5	5.9 ± 1.4	0.63
HbA1c (%)	6.2 ± 1.5	6.3 ± 1.3	0.62

BMI: body mass index, CAD: cardiovascular disease, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, UAP: unstable angina pectoris, TIMI risk score: thrombolysis in myocardial ischemia risk score, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium channel blocker, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, eGFR: estimated glomerular filtration rate, UA: uric acid, and HbA1c: hemoglobin A1c.